The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis
Patients with end-stage renal disease (ESRD) are at an increased risk of cardiovascular disease due to many factors including inflammation and oxidative stress. N-acetylcysteine (NAC) is a thiol-containing anti-oxidant with anti-inflammatory properties. We aimed to assess the effect of three months...
Gespeichert in:
Veröffentlicht in: | Saudi journal of kidney diseases and transplantation 2014, Vol.25 (1), p.66-72 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Patients with end-stage renal disease (ESRD) are at an increased risk of cardiovascular
disease due to many factors including inflammation and oxidative stress. N-acetylcysteine
(NAC) is a thiol-containing anti-oxidant with anti-inflammatory properties. We aimed to assess
the effect of three months treatment with oral NAC on the plasma levels of inflammatory
mediators like interleukin-6 (IL-6) and C-reactive protein (hs-CRP) in patients on hemodialysis
(HD). Twenty-four patients (nine males and 15 females) on maintenance HD were recruited in the
study. Their mean age was 55.3 years. All the patients received oral NAC (600 mg twice a day)
for a period of three months. The serum levels of biomedical parameters and IL-6 and hs-CRP
were measured at baseline and three months after initiation of treatment. A significant decrease in
serum levels of hs-CRP (22.4 vs. 5.2), IL-6 (8.1 vs. 3.6), parathyroid hormone (iPTH) (257.2 vs.
158.8), ferritin (632.0 vs. 515.1) and erythrocyte sedimentation rate (ESR) (54.2 vs. 38.3) was
observed following NAC treatment. Female subjects presented with a significantly higher change
in serum levels of hs-CRP compared with males (23 vs. 5.4). In three subjects who were less than
40 years old, the hs-CRP and IL-6 levels showed an increase following NAC treatment. Our study
found that short-term oral NAC treatment might result in the reduction of IL-6 and hs-CRP in
patients who are on regular HD. This suggests that patients with ESRD may benefit from the antiinflammatory
effects of NAC. |
---|---|
ISSN: | 1319-2442 2320-3838 |
DOI: | 10.4103/1319-2442.124489 |